11,12-Di-O-acetyltenacigenin BCAS# 857897-01-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 857897-01-9 | SDF | Download SDF |
| PubChem ID | 91886693 | Appearance | Powder |
| Formula | C25H36O7 | M.Wt | 448.56 |
| Type of Compound | Steroids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC(=O)C1CCC23C1(C(C(C4C2(O3)CCC5C4(CCC(C5)O)C)OC(=O)C)OC(=O)C)C | ||
| Standard InChIKey | MIGQPMYRGFABCC-BIWLUZBDSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
11,12-Di-O-acetyltenacigenin B Dilution Calculator
11,12-Di-O-acetyltenacigenin B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2294 mL | 11.1468 mL | 22.2936 mL | 44.5871 mL | 55.7339 mL |
| 5 mM | 0.4459 mL | 2.2294 mL | 4.4587 mL | 8.9174 mL | 11.1468 mL |
| 10 mM | 0.2229 mL | 1.1147 mL | 2.2294 mL | 4.4587 mL | 5.5734 mL |
| 50 mM | 0.0446 mL | 0.2229 mL | 0.4459 mL | 0.8917 mL | 1.1147 mL |
| 100 mM | 0.0223 mL | 0.1115 mL | 0.2229 mL | 0.4459 mL | 0.5573 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Motesanib Diphosphate (AMG-706)
Catalog No.:BCC2477
CAS No.:857876-30-3
- Polygalaxanthone XI
Catalog No.:BCN7366
CAS No.:857859-82-6
- Alstolenine
Catalog No.:BCN4808
CAS No.:85769-33-1
- Longistylumphylline A
Catalog No.:BCN4408
CAS No.:857672-34-5
- PSN632408
Catalog No.:BCC5408
CAS No.:857652-30-3
- AT7867
Catalog No.:BCC2536
CAS No.:857531-00-1
- K-252c
Catalog No.:BCC3706
CAS No.:85753-43-1
- IPI-504 (Retaspimycin hydrochloride)
Catalog No.:BCC2126
CAS No.:857402-63-2
- Retaspimycin
Catalog No.:BCC1889
CAS No.:857402-23-4
- Isoflavidinin
Catalog No.:BCN7604
CAS No.:85734-02-7
- 3-Hydroxysarpagine
Catalog No.:BCN4566
CAS No.:857297-90-6
- PF 915275
Catalog No.:BCC7631
CAS No.:857290-04-1
- (-)-Quinpirole hydrochloride
Catalog No.:BCC6917
CAS No.:85798-08-9
- 3-O-Benzyl estrone
Catalog No.:BCC8638
CAS No.:858-98-0
- Vialinin A
Catalog No.:BCC2367
CAS No.:858134-23-3
- Marsdenoside F
Catalog No.:BCN4564
CAS No.:858360-61-9
- 1,3-Dipropyl-8-phenylxanthine
Catalog No.:BCC6664
CAS No.:85872-53-3
- prim-O-Glucosylangelicain
Catalog No.:BCN4409
CAS No.:85889-15-2
- Lincomycin hydrochloride
Catalog No.:BCC9011
CAS No.:859-18-7
- 6-Iodonordihydrocapsaicin
Catalog No.:BCC5860
CAS No.:859171-97-4
- 4-O-Methylhonokiol
Catalog No.:BCN8474
CAS No.:68592-15-4
- Acetyl meldrum's acid
Catalog No.:BCC8805
CAS No.:85920-63-4
- AGN 205728
Catalog No.:BCC5418
CAS No.:859498-05-8
- GR 125487 sulfamate
Catalog No.:BCC7142
CAS No.:859502-43-5
Citrinal B, natural 11 beta-hydroxysteroid dehydrogennase type 1 inhibitor identified from structure-based virtual screening.[Pubmed:28962943]
Fitoterapia. 2017 Nov;123:29-34.
Citrinal B, a tricyclic compound from endophytic fungus Colletotrichum capsici in our previous studies, exhibited significant inhibitory activity against 11beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) in vitro and showed strong binding affinity to 11beta-HSD1. Moreover, citrinal B treatments decreased the lipid droplet accumulation associate with the inhibition of 11beta-HSD1 expression in differentiate induced 3T3-L1 preadipocytes. Furthermore, the molecular docking demonstrated that citrinal B coordinated in the active site of 11beta-HSD1 is essential for the ability of diminishing the enzyme activity.
Synthesis and biological evaluation of novel 6,11-dihydro-5H-benzo[e]pyrimido- [5,4-b][1,4]diazepine derivatives as potential c-Met inhibitors.[Pubmed:28938137]
Eur J Med Chem. 2017 Nov 10;140:212-228.
Over expression of c-Met tyrosine kinase is known to promote tumorigenesis and metastasis, as well as to cause therapeutic resistance. Herein a series of novel 6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepine derivatives were designed, synthesised and evaluated for their c-Met kinase inhibition. Compounds 17e, 17f, 18a, and 18b were further examined for their anti-proliferative activities against four typical cancer cell lines (PC-3, Panc-1, HepG2, and Caki-1). The promising compound 17f was identified as a multi-target receptor tyrosine kinase inhibitor, which also displayed favourable pharmacokinetic properties in rats, had an acceptable safety profile in preclinical studies, and significant anti-tumour activity in the Caki-1 tumour xenograft model.
LncRNA ZEB1-AS1 contributes to STAT3 activation by associating with IL-11 in B-lymphoblastic leukemia.[Pubmed:28861713]
Biotechnol Lett. 2017 Dec;39(12):1801-1810.
OBJECTIVE: To investigate the role of lncRNA ZEB1-AS1 in B-lineage acute lymphoblastic leukemia (B-ALL). RESULTS: ZEB1-AS1 levels were aberrantly up-regulated in B-ALL. All correlated with STAT3 activation and IL-11 production. Moreover, a high level of ZEB1-AS1 predicted poor prognosis of B-ALL patients. Mechanistically, ZEB1-AS1 could bind to IL-11 and promote IL-11 stability. Down-regulation of ZEB1-AS1 decreased IL-11 production of human bone marrow stromal cells (BMSCs), which led to suppressed proliferation and inhibited IL-11/STAT3 pathway in BALL-1 cells. CONCLUSIONS: ZEB1-AS1 promotes the activation of IL-11/STAT3 signaling pathway by associating with IL-11 in B-ALL.
